Key facts:
GLP-1 receptor agonists have surged into the spotlight for their remarkable effectiveness in managing type 2 diabetes and obesity. However, despite widespread discussion among pharmaceutical experts and the general public, the impact of GLP-1 on the MedTech industry remains largely underexplored.
Through insights gleaned from this survey and comprehensive interviews with senior MedTech executives, this study delves into the implications of GLP-1's expansion for the MedTech sector.